Pacific Edge Reports Wider FY2026 Loss as Medicare Recovery Becomes Central Turnaround Focus
Pacific Edge Reports Wider FY2026 Loss as Medicare Recovery Becomes Central Turnaround Focus
Pacific Edge Limited reported a difficult FY2026, with operating revenue falling sharply as the company continued to deal with the loss of Medicare coverage in the United States. The bladder cancer diagnostics company posted operating revenue of NZ$11.5 million, down from NZ$21.8 million in FY2025, while net loss after tax widened to NZ$35.8 million.
Revenue Falls After Medicare Coverage Loss
The company said its FY2026 results were heavily affected by the earlier loss of Medicare and Medicare Advantage coverage. This reduced reimbursement access pressured U.S. test volumes and lowered commercial activity for its Cxbladder products.
Total laboratory throughput fell 16.3% to 24,190 Cxbladder tests, while commercial tests declined 23.8% to 18,783 tests. Despite this, Pacific Edge noted that volumes were supported by growth from Southern California Permanente Medical Group and the Asia-Pacific region.
Cxbladder Remains Core to Pacific Edge’s Strategy
Pacific Edge’s main products are its Cxbladder urine-based diagnostic tests. These tests are designed to help doctors assess patients with blood in the urine and monitor people with non-muscle invasive bladder cancer.
The company continues to argue that Cxbladder can help improve clinical pathways by identifying lower-risk patients, reducing unnecessary procedures, and supporting more efficient use of healthcare resources.
Cost Control Helps Reduce Cash Burn
Although revenue was weaker, Pacific Edge made progress in lowering expenses. The company reduced operating expenses by 9.5% year over year and cut its average monthly cash burn to NZ$2.4 million in the second half of FY2026, compared with NZ$3.3 million in the first half.
Management said this cost discipline was important because the company needed to preserve capital while maintaining enough U.S. market presence to benefit if Medicare coverage is restored.
Medicare Recovery Is the Main Catalyst
The most important development for Pacific Edge is its effort to regain Medicare reimbursement. After the FY2026 balance date, Novitas published a draft Local Coverage Determination for urine-based biomarkers in patients with microhematuria. The draft proposes coverage for Cxbladder Triage and Cxbladder Triage Plus.
This is significant because Medicare coverage could reopen a major revenue channel in the United States. Pacific Edge said final effective coverage could arrive by the end of the 2026 calendar year, although the process still depends on regulatory and administrative steps.
Capital Raise Strengthens Balance Sheet
Pacific Edge ended FY2026 with NZ$7.8 million in cash, cash equivalents, and short-term deposits. After year-end, the company completed a NZ$25.4 million placement and launched a retail offer of up to NZ$6 million.
The new funds are expected to support operations, product development, evidence generation, and the company’s Medicare recovery strategy.
Outlook
Pacific Edge enters FY2027 with clear challenges and clear opportunities. The financial pressure from lost Medicare coverage remains serious, but lower costs, fresh capital, and progress toward possible Medicare reimbursement give the company a stronger base for recovery.
For investors, the key question is whether Pacific Edge can convert Medicare progress into sustainable revenue growth. If coverage is restored and test volumes recover, the company may be better positioned to rebuild its U.S. business. However, if reimbursement delays continue, cash management and commercial discipline will remain critical.
#PacificEdge #PFGTF #Cxbladder #HealthcareStocks #SlimScan #GrowthStocks #CANSLIM